White David P
Harvard Medical School, Boston, MA 02115, USA.
Sleep Med Clin. 2016 Jun;11(2):203-12. doi: 10.1016/j.jsmc.2016.01.007. Epub 2016 Apr 8.
The concept of pharmacologic therapy for obstructive sleep apnea (OSA) treatment has always been considered but no agent has had a large enough effect size to drive substantial adoption. A new construct of the pathophysiology of OSA is that there are 4 primary physiologic traits that dictate who develops OSA. These traits vary substantially between patients, meaning OSA may develop for quite different reasons. This encourages new thinking regarding pharmacologic therapy and continued attempts to find the ideal or acceptable drug.
阻塞性睡眠呼吸暂停(OSA)治疗的药物疗法概念一直备受关注,但尚无一种药物具有足够大的效应量以推动其广泛应用。OSA病理生理学的一种新构想是,有4种主要生理特征决定了谁会患上OSA。这些特征在患者之间差异很大,这意味着OSA可能因截然不同的原因而发生。这促使人们对药物疗法进行新的思考,并持续努力寻找理想或可接受的药物。